e-learning resources

Effect of once daily (o.d.) mometasone/indacaterol/glycopyrronium (MF/IND/GLY) vs o.d. MF/IND and twice daily (b.i.d.) fluticasone/salmeterol (FLU/SAL) with respect to age, age at asthma-onset and BMI at baseline: Subgroup analysis from IRIDIUM study

H. Kerstjens (Groningen, Netherlands), D. Lawrence (Basel, Switzerland), K. Mezzi (Basel, Switzerland), D. Brittain (Basel, Switzerland), X. Jaumont (Basel, Switzerland), K. Chapman (Toronto, Canada)

Source: International Congress 2022 – Clinical treatment of asthma
Session: Clinical treatment of asthma
 Session type: Thematic Poster
 Number: 3853

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
H. Kerstjens (Groningen, Netherlands), D. Lawrence (Basel, Switzerland), K. Mezzi (Basel, Switzerland), D. Brittain (Basel, Switzerland), X. Jaumont (Basel, Switzerland), K. Chapman (Toronto, Canada). Effect of once daily (o.d.) mometasone/indacaterol/glycopyrronium (MF/IND/GLY) vs o.d. MF/IND and twice daily (b.i.d.) fluticasone/salmeterol (FLU/SAL) with respect to age, age at asthma-onset and BMI at baseline: Subgroup analysis from IRIDIUM study. 3853

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.